GE HealthCare Technologies Reports Q2 Earnings and Outlook
In its second-quarter earnings report for fiscal year 2026, GE HealthCare Technologies (NASDAQ:GEHC) reported strong order growth of 11% year over year, a record backlog of $23.9 billion, and organic revenue growth of 3.5%, reaching $5.3 billion. The Advanced Imaging Solutions segment grew by 5% organically, while Pharmaceutical Diagnostics saw robust performance with 14.6% organic growth. However, the Patient Care Solutions segment continued to struggle, reporting a 13.5% revenue decline and negative EBIT due to component shortages and fulfillment issues. Management noted ongoing challenges but expects improvement in the second half of the year and is considering strategic options for this underperforming unit. The company maintained its full-year outlook for organic sales growth between 3%-4%, adjusted EPS of $4.80-$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro will be departing soon, with George Newcomb stepping in as interim CFO during the search for a successor.